top of page
Our Impact Reports
2024 Impact Report
Black Opal Ventures portfolio companies are addressing critical problems in healthcare, life sciences, infrastructure, and security.
Impact Highlights
What they do: Ansa is redefining gene synthesis with a proprietary enzymatic method that enables the production of long, complex DNA sequences previously unreachable by chemical methods.
Impact: Ansa’s aqueous, low-waste synthesis process eliminates hazardous byproducts and improves precision and efficiency—supporting the next generation of cell and gene therapies, synthetic biology, and advanced biomanufacturing.
.png)
"This report details our commitment to impact. Each of our portfolio companies has a positive impact on the most pressing problems in healthcare. In some instances, companies directly work with patients; others have critical infrastructure technology to improve safety, quality, value and equity in the industry."
Dr. Tara Bishop, Managing Director and Co-Founder
Impact Reports
At Black Opal Ventures, value creation goes beyond capital. We believe in building a healthier, more connected innovation ecosystem – one where emerging talent has access to hands-on learning, and founders benefit from shared insight and shared infrastructure. Through firm-led initiatives like the BOV Institute and our Fellows Program, we’re opening doors, sharing knowledge, and creating more pathways into the world of venture.
Next
bottom of page